The FDA has approved Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), a new once-daily CFTR modulator for people with cystic fibrosis (CF) ages 6 and older.
Alyftrek is available to those with CFTR mutations eligible for Trikafta, as well as 31 additional rare mutations that were previously ineligible for any modulator therapy.
Alyftrek provides a new treatment option, particularly for those who cannot tolerate Trikafta. Clinical trials have shown lung function improvements comparable to Trikafta, with even greater reductions in sweat chloride levels.
The once-daily dosing schedule also offers a more convenient regimen for people with CF.
